GlassScriptPhysician profile
Donna L Coley
NPI 1932712452
$2,467.59
in general payments reported to CMS, 2019-2025
21 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.39 · 2023: $244 · 2024: $990 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.75 | 2023-2025 | |
| Novo Nordisk INC | $477.09 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $438.27 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.11 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $134.97 | 2024-2025 | Jardiance, Mounjaro, Kisunla |
| Exact Sciences Corporation | $109.92 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $108.36 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $88.83 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $73.10 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.64 | 2023-2025 | Jardiance |
| Dexcom, INC. | $34.93 | 2021-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $32.88 | 2024 | |
| Sumitomo Pharma America, INC. | $32.39 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $24.47 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.40 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $15.65 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2023 | Xifaxan |
| Esperion Therapeutics, INC. | $14.14 | 2023 | Nexletol |
| Lundbeck LLC | $13.50 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $13.33 | 2024 | Rexulti |
| Amgen INC. | $12.72 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Coley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.